

Detection of Kaposi's sarcoma-associated human herpes virus type 8 DNA in biopsy smears of human immunodeficiency virus-infected patients

Marcelo Corti^{1,2*}, María F Villafañe^{1,2}, Humberto Metta^{1,2}, Norberto Trione^{1,2}, Patricia Baré³ and Leonardo Gilardi⁴

¹HIV/AIDS Department, Infectious Diseases F. J. Muñiz Hospital, Buenos Aires, Argentina

²Medicine Department, Infectious Diseases Orientation, University of Buenos Aires, School of Medicine, Buenos Aires, Argentina

³Virology Laboratory, IIHEMA, IMEX-CONICET, National Academy of Medicine, Buenos Aires, Argentina

⁴Ambulatory Medicine Subcoordinator, OSECAC, Buenos Aires, Argentina

Abstract

Introduction: Epidemic AIDS-associated Kaposi's sarcoma (KS) is the most aggressive form of this neoplasm and is strongly associated with the reactivation of human herpesvirus type 8 (HHV-8), particularly among men who have sex with men.

Objectives: To evaluate the presence of HHV-8 DNA in the biopsy smears of 31 patients with different clinical forms of AIDS-associated KS.

Materials and methods: Epidemiologic, clinic, immunologic and virologic characteristics of 31 HIV infected patients with KS were included in this descriptively and retrospectively analysis from 2010 to 2013. KS was classified in four clinical forms including only cutaneous lesions, only mucosal involvement, mucocutaneous compromise and disseminated disease. The detection of DNA HHV-8 was performed by polymerase chain reaction (PCR) in all biopsy smears by tissue disruption to perform the DNA extraction, DNA purification by spectrophotometry analysis and DNA amplification with specific oligonucleated primers.

Results: Thirty patients were male, the median of age was 34 years and the most frequent risk factor for HIV infection was unprotected sexual contact (90%). The median of time between HIV infections to neoplasm diagnosis was 6 years. In 11 patients (35%) KS was the first defining illness. The median of CD4 T cell count at the time of neoplasm diagnosis was 39 cell/ μ L. The majority of patients (84%) were not receiving highly active antiretroviral therapy (HAART). Clinical forms includes 12 patients with cutaneous KS, 8 patients with mucosal KS, 7 patients with disseminated disease and 4 patients with mucocutaneous involvement. PCR HHV-8 was positive in 24 (77%) biopsy smears. When we analyzed this group the median of age was 34 years, the median of time between HIV infection to neoplasm diagnosis was 9 years, the median the median of CD4 T cell count was 39 cell/ μ L and only 5 patients were receiving HAART at the time of diagnosis. No significant difference was observed between the HHV-8 positive and negative probable due to the small size of the cohort.

Conclusion: Although HHV-8 DNA was detected in a high number of patients in these series, it is possible that other mechanisms may be involved in the pathogenesis of AIDS-associated KS.

Introduction

Kaposi's sarcoma (KS) is a low-grade vascular tumor that may involve the skin, mucosa and viscera. KS was first reported in 1872 by Moritz Kaposi, a Hungarian dermatologist. This first description revealed that the neoplasm affects typically elderly patients of eastern or mediterranean Europeans and was described as "*Idiopathisches Multiples Pigment Sarkom der Haut*" [1,2]. Kaposi's described this tumor a longtime before the advent of the AIDS pandemic as a rare and relatively indolent disease involving the skin on the legs of elderly men [3]. After that, KS was classified in four clinical and epidemiological variants: 1) classic; 2) endemic or African; 3) iatrogenic or post-transplant and 4) epidemic or AIDS associated KS.

Epidemic AIDS associated KS is the most aggressive form of the disease and is strongly associated with the reactivation of human herpes virus type 8 (HHV-8) infection, particularly among men who have sex with men (MSM) [4]. The estimated prevalence of HHV-8 infection in different epidemiological studies demonstrated that half of all MSM are co-infected with HHV-8 and may develop KS within 5 to 10 years [5,6].

The objective of this study was to evaluate the presence of HHV-8 DNA in the biopsy smears of 31 patients with different clinical forms of AIDS-associated KS.

Materials and methods

Epidemiological, clinical, immunological and virological characteristics of 31 HIV-infected patients with KS were included in this descriptive and retrospective analysis from 2010 to 2015. KS was classified in 4 clinical forms: only cutaneous involvement, only mucosal involvement, mucocutaneous compromise and disseminated disease with lymph nodes and visceral involvement. In all patients diagnosis

Correspondence to: Marcelo Corti, Division "B", Infectious Diseases F. J. Muñiz Hospital, Puán 381 2°C 1406 CQG, Buenos Aires, Argentina; **E-mail:** marcelocorti@fibertel.com.ar

Key words: Kaposi's sarcoma, HHV-8, PCR, AIDS

Received: January 05, 2016; **Accepted:** January 20, 2016; **Published:** January 23, 2015

of KS was confirmed by the histopathological examination of biopsy smears obtained from cutaneous or mucosal lesions. The detection of DNA HHV-8 was performed including the following steps: 1) for tissue disruption, fresh and formalin fixed samples were used to perform the DNA extraction and detection of HHV-8. Briefly, disruption and homogenization of the fresh samples were carried out using a scalpel and a needle. For the formalin fixed samples, 10 fine slices of 10 microns were used. The samples were left overnight for complete lysis on a 56°C incubator with 200ul with the chaotropic salt-containing solution to insure the thorough denaturation of macromolecules. The genomic extraction was carried out with a commercial reagent, GenElute Mammalian genomic DNA miniprep kit from Sigma-Aldrich, following manufacturer recommendations; 2) for the DNA purification addition of ethanol causes DNA to bind when the lysate is spun through a silica membrane in a microcentrifuge tube. After several washes, DNA was eluted in 50 µl of a Tris-EDTA solution. The concentration of purified DNA was determined by spectrophotometry analysis; 3) for the DNA amplification PCR was performed with specific primers for the viral capsid (KS3 tccgtgtgtctacgtcc, KS5 agccgaaggattccacc) with 5 to 10 ul of DNA in a total volume of 50 ul, with 1 ul of each primer (20 mM), 10 mM Tris/HCl (pH 8.3), 50 mM KCl, 1.5 mM MgCl₂, each deoxynucleoside triphosphate at a concentration of 200 mM and 1.25 U Taq DNA polymerase (Promega). After an initial denaturation step at 95°C for 5 min, 40 cycles of PCR at 95°C for 30s, 58°C for 30s, 72°C for 30s were carried out with a final extension at 72°C of 10 min. A 233-nucleotide fragment of the viral capsid was amplified performing a PCR with specific oligonucleotide primers [7]. The PCR products were analyzed on a 2% agarose gel stained with ethidium bromide. All PCR runs included positive and negative controls.

Results

During the 5-year period, 31 HIV infected patients were diagnosed with KS. Thirty patients were male, the median of age was 34 years and the most frequent risk factor for HIV infection was unprotected sexual contact (90%). The median time between HIV-infection to neoplasm diagnosis was 6 years and the median of CD4 T-cell count at the time of neoplasm diagnosis was 39 cell/µL. KS was the first AIDS-defining illness in 11 (35%) patients. The majority of patients (84%) were not receiving highly active antiretroviral therapy (HAART). Epidemiological, clinical and immunological characteristics are listed in table 1. Clinical forms includes 12 patients with cutaneous KS, 8 patients with mucosal KS, 7 patients with disseminated disease and 4 patients with mucocutaneous involvement. PCR HHV-8 was positive in 24 (77%) biopsy smears. When we analyzed only this group, the median of age was 34 years, the median of time between HIV-infection to neoplasm diagnosis was 9 years, the median of CD4 T-cell count was 39 cell/µL and only 5 patients were receiving HAART at the time of diagnosis. No significant difference was observed between the HHV-8 positive and negative results probable due to the small size of the cohort. Clinical forms of KS between patients with PCR HHV-8 (+) and PCR HHV-8 (-) in biopsy smears are detailed in table 2.

Table 1. Epidemiological, clinical and immunological characteristics of a series of 31 HIV patients with KS in comparison only with PCR HHV-8 (+) in biopsy smears.

	Total of patients n:31	HHV-8 (+) n:24
Age (median)	34	34
CD4 T cell count/µL (median)	39	39
With HAART in the onset of KS	5 (16%)	5 (20%)
Median time since HIV infection	6 years	9 years
Opportunistic diseases	20 (64.5%)	15 (62.5%)

Table 2. Clinical forms of KS between patients with PCR HHV-8 (+) and PCR HHV-8 (-) in biopsy smears.

Clinical Forms of KS	PCR HHV-8 (+) n: 24	PCR HHV-8 (-) n: 7
Cutaneous KS	9 (37.5%)	3 (43%)
Mucosal KS	7 (29.1%)	1 (14%)
Mucocutaneous KS	4 (16.7%)	0
Disseminated KS	4 (16.7%)	3 (43%)
Opportunistic diseases	20 (64.5%)	15 (62.5%)

Discussion

KS is an AIDS defining neoplasm that is strongly related with HHV-8 infection especially in patients with other sexually transmitted diseases and in the HIV seropositive subjects. Epidemiologic evidence indicated that AIDS-associated KS may have an infectious etiology. MSM AIDS patients are approximately 20 times more likely than hemophilic patients to develop KS and KS may be associated to specific sexual practice among MSM with AIDS [8]. The same herpes virus-like DNA sequences are present in AIDS-associated Kaposi's sarcoma, classic Kaposi's sarcoma, and the Kaposi's sarcoma that occurs in HIV-negative homosexual men [8]. Since the initial detection of HHV-8 in KS biopsy smears, some serological evidence implicates this viral agent with the development of the neoplasm. However, HHV-8 infection is a necessary factor but not sufficient condition in the etiology of all clinical forms of KS and not only to the AIDS-related variety [9]. Histopathological characteristics of KS include a wide spectrum of lesions ranged from pre-KS lesions also known as an *in situ* form of KS to the anaplastic KS, also named pleomorphic KS. Initial KS lesions include abnormal capillary-like vessels in an inflammatory infiltrate and, in some cases, a lymphangiogenesis arising in a setting of chronic lymphedema. On the other hand the anaplastic KS is an infiltrative solid tumor characterized by a proliferation of spindle tumor cells without vascular spaces seen mainly in AIDS-associated KS. This aggressive variant represents a greater degree of cellular and nuclear atypia, with high mitotic index and occasional necrosis. In the echymotic KS, the intradermal proliferation is accompanied by an extensive red blood cell extravasation (purpura effect) [10].

The global seroprevalence of HHV-8 is low, in contrast to other herpesvirus. The prevalence varies from 5% or less in the United States to more than 85% among children of African countries. HHV-8 DNA has been detected in oral epithelial cells and is eliminated in saliva, in B lymphocytes and mononuclear cells in the semen. The virus also can be detected in a cell-free state in the blood during the early phase of the natural history of the disease [11,12]. The different prevalence rates can be influenced by the transmission patterns and it is possible that the most important HHV-8 transmission source occurs primary via domestic or non sexual contact that involves saliva [13].

HHV-8 has a high ability to infect a range of cells including typical KS spindle cells, endothelial cells of the vascular space of KS lesions, monocytes in KS lesions, B lymphocytes in the peripheral blood, primary effusion lymphomas and Multicastelman-related neoplasia and in keratinocytes of the skin [14]. Like other herpesvirus, HHV-8 remains latent within these cells and develops a variety of mechanisms to evade the host immune system.

Pauk *et al.* [15] in a cohort of 50 patients HIV seropositive, detected HHV-8 in 34% of oropharyngeal samples, 5% of semen samples, 1% of anal samples and 0.3% of urethral samples. In the comparison with oral samples with genital and anal samples, the detection of HHV-8

DNA in oral epithelial cells suggests that these cells can be a reservoir of the virus ($p < 0.001$).

Not all the persons infected by HHV-8 develop KS [16]. Orozco *et al.* [17] studied 24 patients with KS; 22 of them were seropositive for HIV. In the group of patients with KS and HIV, 83.3% were seropositive for HHV-8. In other studies the presence of detectable antibodies against HHV-8 was from 11% to 54% in the HIV-seropositive patients [18-21].

In a large cohort of patients co-infected by HIV and HHV-8, Martin *et al.* detected that the presence of HHV-8 antibodies preceded and it was strongly associated with the subsequent development of KS. In the same study, the median time to develop KS in the co-infected subjects was approximately 10 years [22].

Chang *et al.* [7] analyzed 27 tissue samples of patients with KS by three different techniques. Southern Blot DNA hybridization in comparison with PCR. PCR was more sensitive (93%) than Southern Blot hybridization (78%) to detect DNA HHV-8. In our cohort PCR was positive in 77% of biopsy smears.

HHV-8 infection alone appears to be insufficient for the development of KS. The HHV-8 life cycle presents two different phases: a primary and generally asymptomatic infection followed by a latent period and a lytic period characterized by the viral replication.

It is possible that other mechanisms must be involved in the pathogenesis of HIV-associated KS. In this aspect HIV infection can be a cofactor for the development of KS but it is important to emphasize that HIV is not necessary for KS occurrence. Despite other cofactors may exist, none of them have the importance of HIV co-infection.

References

1. Boschhoff C, Weiss RA (2001) Epidemiology and pathogenesis of Kaposi's sarcoma-associated herpesvirus. *Philos Trans R Soc Lond B Biol Sci* 356: 517-534. [\[Crossref\]](#)
2. Kaposi M (1872) Idiopathisches multiples pigment sarkom der Haut. *Arch Derm Syph* 4: 265-73.
3. Haubrich WS (2003) Kaposi of Kaposi's sarcoma. *Gastroenterology* 125: 327.
4. Nawar E, Mbulaiteye SM, Gallant JE (2005) Risks factors for Kaposi's sarcoma among HHV-8 seropositive homosexual men with AIDS. *Int J of Cancer* 115: 296-300.
5. Viejo-Borbolla A, Schultz TF (2003) Kaposi's sarcoma-associated herpesvirus (KSHV/HHV8): key aspects of the epidemiology and pathogenesis. *AIDS reviews* 5: 222-229. [\[Crossref\]](#)
6. Hansen A, Boshoff C, Lagos D (2007) Kaposi sarcoma as a model of oncogenesis and cancer treatment. *Exp Rev Anticancer Ther* 7: 211-220. [\[Crossref\]](#)
7. Chang Y, Cesarman E, Pessin MS (1994) Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. *Science* 266: 1865-1869. [\[Crossref\]](#)
8. Moore PS, Chang Y (1995) Detection of herpesvirus-like DNA sequences in Kaposi's sarcoma in patients with and those without HIV infection. *N Engl J Med* 332: 1181-1185. [\[Crossref\]](#)
9. Simonart T (2006) Role of environmental factors in the pathogenesis of classic and African-endemic Kaposi's sarcoma. *Cancer letters* 244: 1-7.
10. Radu O, Pantanowitz L (2013) Kaposi Sarcoma. *Arch Pathol Lab Med* 137: 289-294. [\[Crossref\]](#)
11. Huang YQ, Li JJ, Poiesz BJ (1997) Detection of herpesvirus-like DNA sequences in matched specimens of semen and blood from patients with AIDS-related Kaposi's sarcoma by polymerase chain reaction in situ hybridization. *Am J Pathol* 150: 147-153. [\[Crossref\]](#)
12. Harrington WJ, Bagastra O, Sosa CE (1996) Human herpesvirus type 8 DNA sequences in cell-free plasma and mononuclear cells of Kaposi's sarcoma patients. *J Infect Dis* 174: 1101-1105. [\[Crossref\]](#)
13. Dukers NH, Rezza G (2003) Human herpesvirus 8 epidemiology. What we do and what we don't know. *AIDS* 17: 1717-1730.
14. Sadagopan S, Sharma-Walia N, Veettil MV, Raghu H, Sivakumar R, et al. (2007) Kaposi's sarcoma-associated herpesvirus induces sustained NF-kappa B activation during de novo infection of primary human dermal microvascular endothelial cells that is essential for viral gene expression. *J of Virol* 81: 3949-3968. [\[Crossref\]](#)
15. Pauk J, Huang ML, Brodie SJ, Wald A, Koelle DM, et al. (2000) Mucosal shedding of human herpesvirus 8 in men. *NEJM* 343: 1369-1377. [\[Crossref\]](#)
16. Ganem D (2006) KSHV infection and the pathogenesis of Kaposi's sarcoma. *Annual Review of Pathol* 1: 273-296. [\[Crossref\]](#)
17. Orozco B, Gomez LM, Estrada S, Restrepo BN, Cataño JC (2007) Relationship between human herpes virus 8 and Kaposi sarcoma in HIV positive and negative patients. *Infection* 11: 111-116. [\[Crossref\]](#)
18. Blackburn DJ, Osmond D, Levy JA, Lennette ET (1999) Increased human herpesvirus 8 seroprevalence in young homosexual men who have multiple sex contacts with different partners. *J Infect Dis* 179: 237-239. [\[Crossref\]](#)
19. O'Brien TR, Kedes D, Ganem D, Macrae DR, Rosenberg PS, et al. (1999) Evidence for concurrent epidemics of human herpesvirus 8 and human immunodeficiency virus type 1 in US homosexual men: rates, risk factors, and relationship to Kaposi's sarcoma. *J Infect Dis* 180: 1010-1017. [\[Crossref\]](#)
20. Kedes DH, Operskalski E, Busch M, Kohn R, Flood J, et al. (1996) The seroepidemiology of human herpesvirus 8 (Kaposi's sarcoma-associated herpesvirus): distribution of infection in KS risk groups and evidence for sexual transmission. *Nat Med* 2: 918-924. [\[Crossref\]](#)
21. Gao SJ, Kingsley L, Li M, Zheng W, Parravicini C, et al. (1996) KSHV antibodies among Americans, Italians, and Ugandans with and without Kaposi's sarcoma. *Nat Med* 2: 925-928. [\[Crossref\]](#)
22. Martin JN (2007) The epidemiology of KSHV and its association with malignant disease. Human Herpesviruses: Biology, Therapy, and Immunoprophylaxis. Cambridge: Cambridge University Press, UK.